Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Riferminogene pecaplasmide

Drug Profile

Riferminogene pecaplasmide

Alternative Names: Cardiovascular gene therapy - sanofi-aventis; Cardiovascular therapeutic protein - sanofi-aventis; DNA-based delivery of Fibroblast Growth Factor 1 (FGF-1) - sanofi-aventis; FGF-1 gene therapy; NV1-FGF; Riferminogen pecaplasmid; Temusi; XRP 0038

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vical
  • Developer Sanofi; sanofi-aventis
  • Class Anti-ischaemics; Gene therapies
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Ischaemic heart disorders; Peripheral arterial disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Dec 2011 Discontinued - Phase-III for Peripheral arterial disorders in Australia (IM)
  • 31 Dec 2011 Discontinued - Phase-III for Peripheral arterial disorders in Belarus (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top